Skip to main content
Signal8

Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

$GILDPress releaseNov 4, 2026, 9:15 AM ETRead the release

Gilead and Kite will present 23 abstracts, including 7 orals, at the ASH annual meeting December 12-15, 2026, spanning the oncology pipeline and cell-therapy portfolio. The centerpiece is 18-month minimum follow-up from the pivotal Phase 2 iMMagine-1 study of anito-cel in relapsed/refractory multiple myeloma, plus new comparative analyses versus bispecifics and competing CAR-T therapies; anito-cel's FDA BLA is under review with a PDUFA date of December 23, 2026.

Key figures

Drug Name
anitocabtagene autoleucel (anito-cel)
Phase Of Trial
Phase 2
Pdufa date
December 23, 2026
Zuma 12 followup
5-year
Oral presentations
7
Presentations total
23
Imumagine 1 followup
18-month minimum

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    GILD: Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026 — AI Analysis | Signal8